The epidemiology of severe sepsis syndrome and its treatment with recombinant human activated protein C

Author： Doig Christopher James   Laupland Kevin B   Zygun David A   Manns Braden J  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.4, Iss.10, 2003-10, pp. : 1789-1799

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Coagulopathy and the role of recombinant human activated protein C in sepsis and following polytrauma

By Dahabreh Ziad   Dimitriou Rozalia   Chalidis Byron   Giannoudis Peter V  

Expert Opinion on Drug Safety, Vol. 5, Iss. 1, 2006-01 ,pp. : 67-82

Informa Healthcare

Access to resources Recommend Favorite

Drotrecogin Alfa (Activated): A Pharmacoeconomic Review of its Use in Severe Sepsis

By Frampton J.E.   Foster R.H.  

PharmacoEconomics, Vol. 22, Iss. 7, 2004-01 ,pp. : 445-476

Adis International

Access to resources Recommend Favorite

Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis

By McCoy Christopher  

Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. : 625-637

Informa Healthcare

Access to resources Recommend Favorite

Activated protein C provides a new therapeutic option in sepsis

By  

Inpharma, Vol. 1, Iss. 1279, 2001-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Activated protein C in the treatment of acute lung injury and acute respiratory distress syndrome

By Cornet Alexander D   van Nieuw Amerongen Geerten P   Beishuizen Albertus   Schultz Marcus J   Girbes Armand RJ   Groeneveld AB Johan  

Expert Opinion on Drug Discovery, Vol. 4, Iss. 3, 2009-03 ,pp. : 219-227

Informa Healthcare

Access to resources Recommend Favorite